臨床検査68巻6号

2024年06月発行

今月の特集 免疫・アレルギー性肺疾患と検査 疾患各論

膠原病に伴う肺障害

著者： 榎本紀之¹²

所属機関： ¹浜松医科大学内科学第2講座 ²浜松医科大学保健管理センター

ページ範囲：P.708 - P.716

Point

●膠原病（CTD）では，間質性肺疾患（ILD）のみでなく気道病変，血管病変など多彩な肺病変を合併し，特にILDと肺高血圧症（PH）の合併が予後を悪化させる．

●全身性強皮症（SSc）や多発性筋炎/皮膚筋炎（PM/DM），混合性結合組織病（MCTD）においてILDの合併率が高い．

●CTD診断時には，胸部CTや聴診などによるILDの早期発見，早期治療開始が重要であり，予後を改善する．

●CTD関連のILDの診断には，日和見感染や薬剤性肺障害の鑑別診断が必要である．

参考文献

1）日本呼吸器学会，日本リウマチ学会合同膠原病に伴う間質性肺疾患診断・治療指針2020作成委員会（編）：膠原病に伴う間質性肺疾患診断・治療指針2020，日本呼吸器学会，2020

2）Cano-Jiménez E, Vázquez Rodríguez T, Martín-Robles I, et al：Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. Sci Rep　11：9184，2021

3）Fischer A, du Bois R：Interstitial lung disease in connective tissue disorders. Lancet　380：689-698，2012

4）Patterson KC, Shah RJ, Porteous MK, et al：Interstitial Lung Disease in the Elderly. Chest　151：838-844，2017

5）Joy GM, Arbiv OA, Wong CK, et al：Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev　32：220210，2023

6）Oldham JM, Adegunsoye A, Valenzi E, et al：Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J　47：1767-1775，2016

7）Enomoto N, Suda T, Kato M, et al：Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest　130：22-29，2006

8）Natsuizaka M, Chiba H, Kuronuma K, et al：Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med　190：773-779，2014

9）Park IN, Kim DS, Shim TS, et al：Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest　132：214-220，2007

10）Suda T, Kaida Y, Nakamura Y, et al：Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med　103：846-853，2009

11）Enomoto N, Naoi H, Mochizuka Y, et al：Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases. BMC Pulm Med　22：387，2022

12）Park JW, Curtis JR, Choi SR, et al：Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab. Arthritis Rheumatol　75：2036-2044，2023

13）Tyndall AJ, Bannert B, Vonk M, et al：Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis　69：1809-1815，2010

14）Distler O, Assassi S, Cottin V, et al：Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J　55：1902026，2020

15）Strollo D, Goldin J：Imaging lung disease in systemic sclerosis. Curr Rheumatol Rep　12：156-161，2010

16）Wongkarnjana A, Ryerson CJ：Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?. Eur Respir J　55：2000894，2020

17）Goh NS, Desai SR, Veeraraghavan S, et al：Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med　177：1248-1254，2008

18）Distler O, Highland KB, Gahlemann M, et al：Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med　380：2518-2528，2019

19）Yamasaki Y, Yamada H, Ohkubo M, et al：Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol　38：1636-1643，2011

20）Takato H, Waseda Y, Watanabe S, et al：Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia--with or without PM/DM. Respir Med　107：128-133，2013

21）Tanizawa K, Handa T, Nakashima R, et al：HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med　105：1380-1387，2011

22）Fujisawa T, Hozumi H, Kono M, et al：Prognostic factors for myositis-associated interstitial lung disease. PLoS One　9：e98824，2014

23）Hozumi H, Fujisawa T, Nakashima R, et al：Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med　121：91-99，2016

24）Kurita T, Yasuda S, Oba K, et al：The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford)　54：1536，2015

25）Fujisawa T, Hozumi H, Kamiya Y, et al：Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial. Respirology　26：370-377，2021

26）Sugiyama Y, Yoshimi R, Tamura M, et al：The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. Arthritis Res Ther　20：7，2018

27）Flaherty KR, Wells AU, Cottin V, et al：Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med　381：1718-1727，2019

28）Raghu G, Remy-Jardin M, Richeldi L, et al：Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med　205：e18-e47，2022

29）Nakajima A, Inoue E, Tanaka E, et al：Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol　39：360-367，2010

30）Kim EJ, Collard HR, King TE Jr：Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest　136：1397-1405，2009

31）Yamakawa H, Ogura T, Kameda H, et al：Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). J Clin Med　10：3806，2021

32）Tsuchiya Y, Takayanagi N, Sugiura H, et al：Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J　37：1411-1417，2011

33）Enomoto N, Homma S, Inase N, et al：Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. Thorax　77：143-153，2022

34）Kono M, Nakamura Y, Enomoto N, et al：Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS One　9：e94775，2014

35）Enomoto N, Oyama Y, Enomoto Y, et al：Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. Chron Respir Dis　16：1479972318809476，2019